A Phase IIa Study of SGM-1019 in Non-alcoholic Steatohepatitis (NASH) Patients

Trial Profile

A Phase IIa Study of SGM-1019 in Non-alcoholic Steatohepatitis (NASH) Patients

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs SGM 1019 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Second Genome
  • Most Recent Events

    • 09 Apr 2018 According to a Second Genome media release, the company expect to initiate this trial in 2H 2018.
    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top